Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1627 1642 1644 1671
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16477505 | VALIDATION OF NEOEPITOPE-BASED TREATMENT | Non-Final OA | NANT HOLDINGS IP, LLC |
| 17075238 | OVERLOAD AND ELUTE CHROMATOGRAPHY | Final Rejection | Genentech, Inc. |
| 17762215 | METHODS FOR TREATING METASTATIC TRIPLE NEGATIVE BREAST CANCER WITH ANTI-PD-1 ANTIBODIES | Final Rejection | Merck Sharp & Dohme LLC |
| 18247226 | COMBINATION OF ANTIBODIES FOR TREATING CANCER WITH REDUCED CYTOKINE RELEASE SYNDROME | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17612204 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18287539 | Site-Specific Modification of Glycoproteins Through Transglutaminase-Mediated Conjugation | Non-Final OA | Northeastern University |
| 17460986 | System and Process for Production of Isotopes and Isotope Compositions | Non-Final OA | Battelle Memorial Institute |
| 17782930 | USE OF A PCSK9 INHIBITOR TO TREAT HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Final Rejection | SANOFI BIOTECHNOLOGY |
| 17767398 | CANCER COMBINATION TREATMENTS USING ANTI-STAT3 NUCLEIC ACID CONJUGATES | Non-Final OA | CITY OF HOPE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy